Research
PNC-27 Fact Sheet
| Molecular formula: | C188H293N53O44S |
| Molecular weight: |
4031.7 g/mol
|
| Purity: | 98.5%+ |
| Research Applications: |
|
PNC-27 Peptide Research
PNC-27 is an anti-cancer peptide initially studied for its unique mechanism of inducing cancer cell cytotoxicity by binding to HDM-2 in the membranes of cancer cells. The peptide contains the HDM-2 binding domain of p53 and causes tumor cell death by membranolysis.
It has been shown to induce tumor cell necrosis in both solid and non-solid tissue tumor cells, including a poorly differentiated non-solid tissue human leukemia cell line. PNC-27 and its shorter analog peptide, PNC-28, selectively lyse the membranes of cancer cells, leading to the necrosis of a variety of cancer cell lines and primary human tumors, but not untransformed cells.
PNC-27 as an Anti-Cancer Peptide
PNC-27 is a 32-residue peptide with anti-cancer activity that selectively kills cancer cells without harming normal cells. It contains an HDM-2 binding domain and a cell-penetrating peptide (CPP) leader sequence[1]. PNC-27 works by binding to HDM-2 associated with the plasma membrane of cancer cells, inducing the formation of pores and causing tumor cell lysis and necrosis. This mechanism is independent of p53 activity in the cells[2].
The peptide has demonstrated effectiveness against various cancer cell lines, including breast, ovarian, cervical, and leukemia cells. In some cases, PNC-27 has been shown to enhance the efficacy of other anti-cancer agents, such as rapamycin, methotrexate, and the peptide PNC-27, by substantially lowering their IC50 values for cancer cell killing. This suggests that PNC-27 could be a powerful adjunct agent in treating human cancers.
PNC-27’s anti-cancer activity is dependent on its interaction with membrane-bound HDM-2, a zinc finger protein and negative regulator of the p53 pathway, which is often overexpressed by cancer cells and implicated in cancer cell proliferation and survival. The peptide does not kill cancer cells but rather blocks their proliferation. In some studies, PNC-27 has demonstrated synergistic effects with other anti-cancer drugs, such as paclitaxel, in the treatment of ovarian cancer.
Legal Disclaimer
This product is sold as a pure compound for research purposes only and is not meant for use as a dietary supplement. Please refer to our terms and conditions prior to purchase.
Safety Information: Keep this product out of the reach of children. This material has limited research available about it and may result in adverse effects if improperly handled or consumed. This product is not a dietary supplement, but a pure substance, sold as a raw material. We attest exclusively to the quality, purity and description of the materials we provide. This product is for use and handling only by persons with the knowledge and equipment to safely handle this material. You agree to indemnify us for any adverse effects that may arise from improper handling and/or consumption of this product.
The articles and information on products that may be found on this website are provided exclusively for the purposes of providing information and education. These items are not pharmaceuticals or medications, and the Food and Drug Administration has not given permission for the treatment or prevention of any disease, medical condition, or ailment using them.
Reviews
There are no reviews yet.